Veminsyn Secures Nearly RMB 100 Million Strategic Financing, Partners with L'Oréal to Pioneer AI-Driven Biotech Innovation

VCBeat has learned that Synthetic biology recently announced the completion of a strategic round of financing amounting to nearly RMB 100 million, led byL'Oréal GroupwithNice GroupCo-investment,Mumian CapitalServed as the lead financial advisor for the financing. This financing marks another international recognition by industry giants of the company’s leading position in the field of bioactive material innovation. Meanwhile, Synthetic biology and L’Oréal Group have officially entered into a strategic partnership, with both parties to collaborate based on Synthetic biology’sPlant Callus Culture TechnologywithAI-Driven R&D Platform, jointly advancing sustainable beauty solutions and the application of cutting-edge technologies.

As a leading AI biotechnology enterprise in China, Synthetic biology is dedicated to revolutionizing the research, development, and production of bioactive materials through AI and synthetic biology technologies. The company has established a comprehensive platform covering“Raw Material Discovery – Raw Material Evaluation – Sustainable Production”a full-chain R&D system, and leveraging seven core technology platforms to provide the industry with efficient, low-carbon innovative solutions:

· The world’s leading database of bioactive compounds:Encompassing 40 billion bioactive molecules, it leverages AI algorithms for targeted screening and has successfully identified and applied over 200 high-value active ingredients.

· AI Replaces Traditional Experiments:Pioneered the first non-invasive transdermal testing platform based on human Raman spectroscopy, collaborated with international organizations to establish industry standards, annually tested over 500 raw materials, and significantly reduced animal experimentation; the AI-driven efficacy evaluation system increased screening efficiency by a thousand-fold, enabling the screening of millions of compounds per day.

· Green Bio-manufacturing:Pioneered the "semi-solid callus culture technology" to overcome limitations in rare plant resources, yielding extracts with enhanced bioactivity and reduced contamination. The company has established Asia’s largest callus resource bank and completed the domestic filing for the first new ingredient based on this technology: "Epiphyllum oxypetalum Callus Extract."

Currently, Synthetic Biology has obtained filing and certification for 158 new cosmetic ingredients from the National Medical Products Administration (NMPA), successfully achieving full-chain transformation from scientific innovation to large-scale production. It provides core bioactive ingredient support to leading global beauty groups such as L'Oréal, Proya, and Bloomage Biotech.Leveraging its self-developed AI + biotechnology platform and efficient commercial delivery capabilities, Synthetic biology is gradually emerging as a benchmark enterprise in the field of synthetic biology, driving the industry’s low-carbon and intelligent transformation through technology.

Amidst the global wave of transformation in the manufacturing industry, Synthetic Biology centers its strategy on a “three-step” approach—Starting with skincare raw materials, advancing to medical aesthetic products, and ultimately focusing on functional food ingredients.Driven by the dual engines of technological iteration and industrial upgrading, we are building an innovative landscape that covers all scenarios in consumer healthcare:

1. Building a Full Industry Chain Ecosystem
The skincare raw materials business has served leading domestic and international brands such as L'Oréal and Proya, establishing a stable growth engine. Leveraging the commissioning of its GMP-certified facility in Suzhou, medical device products including collagen-based dermal fillers have received successive regulatory approvals, enabling the company to capture high-barrier markets. Meanwhile, through forward-looking investments in functional food ingredients, the company is launching "Tianshan Snow Lotus Stamen Extract," developed using plant callus tissue technology, thereby expanding into the new consumer healthcare sector.

2. Breaking Through Globalization: Strategic Partnerships Leverage International Momentum
The strategic partnership with L'Oréal marks a key milestone,By leveraging an international team and a global compliance framework, the company deeply integrates supply chain resources to enable Chinese bioactive ingredients to transcend geographical boundaries, infusing the global beauty industry with the innovative power of “Intelligent Manufacturing in China.”

3. Technology for All: Low-Carbon Efficiency Reshapes the Industry
By leveraging AI and green biomanufacturing technologies, we reduce R&D costs and environmental impact, making safe and sustainable active ingredients accessible to consumers worldwide.

Amid the global surge in the synthetic biology market, which has surpassed the $100 billion mark, Synthetic Biology has emerged as a favorite among both investors and industry players, thanks to its end-to-end R&D capabilities and commercial delivery strength. Within four years of its establishment, the company has completed five rounds of financing, securing continuous support from leading institutions such as CITIC Capital and ZhenFund.

Barbara LAVERNOS, Deputy Chief Executive Officer of Global Research, Innovation and Technology at L'Oréal Groupstated: “We are delighted to partner with Weiming Shiguang, a cutting-edge Chinese biotechnology company, to drive revolutionary breakthroughs in bioactive ingredients. This strategic investment will integrate Weiming Shiguang’s leading AI-driven design platform and comprehensive biological R&D capabilities with L’Oréal’s extensive scientific expertise in skin, hair, and scalp biology. Together, we are committed to accelerating the identification and development of high-performance, unique active ingredients, while streamlining the process from design to large-scale production. This collaboration marks a significant step forward in L’Oréal’s sustainable innovation efforts, and we look forward to working closely with Weiming Shiguang to achieve this ambitious goal.”

He Yibo, Director of the Board, Vice President, and Director of the Technology Innovation Department at Nice GroupStating: “Synthetic Biology has built rare barriers through its end-to-end R&D capabilities—ranging from the world’s largest database of bioactive ingredients, to pioneering transdermal permeation testing methods based on human Raman spectroscopy, and further to a mass production platform for green plant callus tissues. Synthetic Biology is a highly creative company driven by new-quality productive forces. Such a company aligns with Nice Group’s development path and meets the industry’s expectations. It can be said that the industry has chosen Synthetic Biology.”

Driven by hard-core technology and guided by a global vision, Weiming Shiguang is carving out an innovative course in the wave of synthetic biology, reshaping the global coordinates of China’s intelligent manufacturing. True to its name, this “Light of Weiming” leverages a core of green technology and the momentum of AI innovation, allowing Chinese innovations to shine brilliantly on the global stage.